Bitroziga®(Abirateron)

Metastatic castration-resistant prostate cancer: Bitroziga® 1000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.  Metastatic castra...

Verzalib® (Abemaciclib)

Verzalib® tablets are taken orally with or without food. • Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily. • R...

Lenvata®(Lenvatinib)

Lenvatinib is a kinase inhibitor that is indicated: • For the treatment of patients with locally recurrent or metastatic,  progressive, radioactive iodine-refractory differentiated thyroi...

Sipomid® (Siponimod)

Faxibet plus® ER (Dapagliflozin/Metformin)

Teriflunomide

The recommended dose of Teriflunomide is 7 mg or 14 mg orally once daily. Teriflunomide can be taken with or without food.

TOFAXEL® (Tofacitinib)

Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence ...

Faxibet® (Dapagliflozin)

Dapagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin reduces reabsorption of filtered glucose and increases urinary glucose excretion. Dapagliflozin also reduces sodium r...

Rizolung® (Crizotinib)

Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, HGFR, c-Met, ROS1, and RON. 

Encastry® (enzalutamide)

Enzalutamide is an androgen receptor inhibitor. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in animal model.

Vandesa® (Vandetanib)

In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These recepto...

Simerta® (Osimertinib)

Simerta ® is a kinase inhibitor of epidermal growth factor receptor (EGFR) which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions). ...